Eiger BioPharmaceuticals (NASDAQ:EIGR) slips 10% premarket on light volume in reaction to results from an investigator-sponsored study evaluating Peginterferon Lambda-1a (Lambda) in outpatients with mild and uncomplicated COVID-19.
Lambda, currently in late-stage development for hepatitis delta virus (HDV) infection, failed to separate from placebo as measured by SARS-CoV-2 viral shedding and time to symptom resolution.
The company in-licensed global rights to Lambda from Bristol Myers Squibb (NYSE:BMY).
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.